Advancing COVID-19 Prevention: The Role of PEP With XOCOVA® (ensitrelvir) Clinical Essentials

Overview

The period immediately following COVID-19 exposure represents a critical opportunity for intervention. This program will examine the ongoing burden of COVID-19, review the science supporting early antiviral intervention following exposure, and highlight pivotal Phase 3 SCORPIO-PEP data evaluating XOCOVA (ensitrelvir) for PEP. Attendees will gain practical insights into patient identification, treatment considerations, and real-world implementation scenarios to help reduce the risk of symptomatic COVID-19 following exposure.